Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова (Sep 2016)

Current understanding of the rational diagnostics and treatment of acquired myasthenia gravis. Part 2: treatment

  • S. N. Bardakov,
  • S. A. Zhivolupov,
  • E. R. Barantsevich,
  • M. V. Zakharov,
  • I. N. Samartsev

DOI
https://doi.org/10.24884/1607-4181-2016-23-3-6-11
Journal volume & issue
Vol. 23, no. 3
pp. 6 – 11

Abstract

Read online

Due to the fact that acquired myasthenia gravis is an autoimmune disease, so rational treatment of these patients includes the symptomatic therapy (acetylcholinesterase inhibitors, potassium supplements, potassiumsaving diuretics), short-term immunotherapy (intravenous immunoglobulin, methods of extracorporeal hemocorrection), longterm immunotherapy (glucocorticosteroids, cytotoxic agents, targeted therapies), thymectomy, as well as a number of new promising therapeutic agents. The choice of effective therapy depends on identifying the clinical forms of myasthenia gravis and a complete analysis of autoimmune mechanisms underlying the disease because of similar clinical forms of myasthenia gravis may respond to similar therapies.

Keywords